Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IO102-IO103 |
Trade Name | |
Synonyms | PD-L1/IDO Peptide Vaccine|IO103/IO102 Peptide Vaccine |
Drug Descriptions |
IO102-IO103 is a peptide vaccine comprised of long peptides derived from IDO and PD-L1, which may result in activation of IDO and PD-L1 specific T lymphocytes, potentially leading to increased antitumor immune response (Annals of Oncology 31 (2020): S1176). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C148154 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IO102-IO103 | IO102-IO103 | 0 | 0 |
IO102-IO103 + Nivolumab | IO102-IO103 Nivolumab | 0 | 1 |
IO102-IO103 + Nivolumab and relatlimab-rmbw | IO102-IO103 Nivolumab and relatlimab-rmbw | 0 | 1 |
IO102-IO103 + Pembrolizumab | IO102-IO103 Pembrolizumab | 0 | 5 |